SCHEMBL5002835

SCHEMBL5002835

N#Cc1ccc(CNC(=O)C(CCCN2CCC3(CC2)OC(=O)Nc2ccc(F)cc23)c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 7/20 0.46
TACR1 P25103 6/20 0.46
CCR2 P41597 7/20 0.40
KLKB1 P03952 1/20 0.39
F11 P03951 1/20 0.39
HTR1A P08908 2/20 0.39
DRD2 P14416 2/20 0.39
HTR7 P34969 2/20 0.39
HTR6 P50406 2/20 0.39
CACNA1F O60840 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
HRH2 P25021 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR2A P28223 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
ADRA1B P35368 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631485 0.96 TACR3 (0.49) TACR3TACR1CCR2KLKB1F11
SCHEMBL632023 0.94 TACR3 (0.49) TACR3TACR1CCR2PLD2PLD1
SCHEMBL631093 0.93 TACR3 (0.52) TACR3TACR1CCR2PLD2PLD1
SCHEMBL8184785 0.92 TACR3 (0.48) TACR3TACR1CCR2PLD2PLD1
SCHEMBL8185992 0.91 TACR3 (0.49) TACR3TACR1CCR2PLD2PLD1
SCHEMBL5002936 0.91 TACR3 (0.49) TACR3TACR1CCR2KLKB1PLD2
SCHEMBL631385 0.90 CCR2 (0.49) TACR3TACR1CCR2
SCHEMBL632085 0.90 TACR3 (0.53) TACR3TACR1CCR2PLD2PLD1
SCHEMBL632275 0.89 TACR3 (0.48) TACR3TACR1CCR2PLD2PLD1
SCHEMBL633754 0.89 TACR3 (0.46) TACR3TACR1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470684-B2 Spiropiperidine derivatives as NK3 antagonists HOFFMANN-LA ROCHE INC. (US) 2008-12-30 US disclosed
US-7470684-B2 Spiropiperidine derivatives as NK3 antagonists HOFFMANN-LA ROCHE INC. (US) 2008-12-30 US disclosed
US-7470684-B2 Spiropiperidine derivatives as NK3 antagonists HOFFMANN-LA ROCHE INC. (US) 2008-12-30 US disclosed
US-20080176839-A1 SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-24 US disclosed
US-20080176839-A1 SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-24 US disclosed
US-20080176839-A1 SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176839-A1 SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS ADRB3, KCNK3, KCND3 TACR3 28/4885TACR1 6/4885CCR2 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.